Diabetes and Obesity: Innovations in Mechanisms, Diagnostics, and Patient Care

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Endocrinology".

Deadline for manuscript submissions: 20 October 2026 | Viewed by 615

Editors


E-Mail Website
Guest Editor
Department of Paediatrics, Diabetology and Endocrinology, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland
Interests: diabetes; obesity; lipidology; endocrinology

E-Mail Website
Guest Editor Assistant
Department of Paediatrics, Diabetology and Endocrinology, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland
Interests: diabetes; obesity; lipidology; endocrinology

Special Issue Information

Dear Colleagues,

The global rise in the prevalence of diabetes and obesity is a major challenge to public health systems worldwide. This rise imposes a substantial burden on healthcare systems, contributing to increased morbidity, mortality, and economic costs. Despite significant advances in prevention and treatment, many aspects of the underlying mechanisms, early detection, and long-term management of diabetes and obesity remain insufficiently understood. The growing complexity of these disorders, driven by genetic, metabolic, environmental, and behavioral factors, demands innovative, multidisciplinary, and personalized approaches.

Recent years have shown remarkable progress in areas such as precision and personalized medicine, biomarker discovery, and novel therapeutic strategies. These developments enable early diagnosis, support individualized therapies, and enhance treatment outcomes. At the same time, important challenges persist, including health disparities, access to care, and the integration of emerging technologies into routine clinical practice. Addressing these issues is both timely and essential for advancing research and improving real-world patient care.

This Special Issue aims to present and disseminate recent advances related to the mechanisms, diagnostics, and management of diabetes and obesity. We welcome contributions that explore molecular and cellular pathways, innovative diagnostic tools, clinical interventions, and patient-centered care strategies, as well as interdisciplinary approaches that bridge basic science and clinical applications.

Topics of interest for publication include, but are not limited to, the following:

  • Pathophysiological mechanisms linking obesity and diabetes;
  • Novel biomarkers and diagnostic approaches;
  • Advances in pharmacological and non-pharmacological therapies;
  • Precision medicine and personalized therapeutic strategies;
  • Prevention strategies and lifestyle interventions;
  • Nutritional approaches, dietary patterns, and metabolic health;
  • Novel psychological and behavioral aspects of obesity and diabetes management;
  • Pediatric and adolescent obesity and diabetes, including type 1 diabetes in obese patients.

Long-term complications and comorbidity management

Prof. Dr. Malgorzata Mysliwiec
Guest Editor

Dr. Anna Wołoszyn-Durkiewicz
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes
  • obesity
  • diagnosis
  • patient care
  • endocrinology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

24 pages, 3999 KB  
Systematic Review
Electronic Glycemic Management Systems Versus Conventional Insulin Infusion Protocols in Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis of Non-Randomized Studies
by Adnan Bhat, Abdullah, Asad Zaman, Ali Shan Hafeez, Muhammad Faizan, Abdul Rafae Faisal, Muhammad Asad, Syed Zaeem Ahmed, Shaikh Muhammad Daniyal, Arkadeep Dhali and Juan M. Munoz Pena
Medicina 2026, 62(7), 1287; https://doi.org/10.3390/medicina62071287 - 3 Jul 2026
Viewed by 359
Abstract
Background and Objectives: Electronic glycemic management systems (eGMSs) are increasingly used to guide intravenous insulin infusion for hospitalized patients with diabetic ketoacidosis (DKA), but available comparative evidence remains non-randomized and clinically heterogeneous and includes multiple algorithmically distinct platforms. Methods and Materials: [...] Read more.
Background and Objectives: Electronic glycemic management systems (eGMSs) are increasingly used to guide intravenous insulin infusion for hospitalized patients with diabetic ketoacidosis (DKA), but available comparative evidence remains non-randomized and clinically heterogeneous and includes multiple algorithmically distinct platforms. Methods and Materials: We conducted a systematic review and meta-analysis in accordance with PRISMA guidance and a prospectively registered protocol (PROSPERO: 2025 CRD420251019614). Seven non-randomized studies comprising 3874 hospitalized patients were included; six studies contributed data to the primary meta-analysis of time to DKA resolution. The primary outcome was time to DKA resolution. Secondary outcomes included ICU length of stay (LOS), hospital LOS, duration of insulin infusion, and hypoglycemia (mild and severe). Random-effects models were applied. Results: Six studies contributed to the primary meta-analysis of time to DKA resolution; across the review, seven studies included 3874 patients. The pooled analysis showed no statistically significant difference between groups (SMD −0.04, 95% CI −0.22 to 0.14; I2 = 74.8%). Recorded hypoglycemia was lower among patients managed with eGMS; however, these estimates should be interpreted cautiously because of heterogeneity, serious-to-critical risk of bias, and potential differences in glucose-monitoring and documentation practices. ICU and hospital LOSs and duration of insulin infusion showed no statistically significant differences overall, with heterogeneity across studies. Conclusions: In available non-randomized evidence, eGMS-guided insulin infusion was not associated with a clear difference in time to DKA resolution, ICU length of stay, hospital length of stay, or insulin infusion duration compared with conventional protocols. Lower recorded hypoglycemia was observed with eGMSs, but this finding should be considered hypothesis-generating because of serious-to-critical risk of bias, residual confounding, substantial heterogeneity, and possible detection bias. High-quality randomized trials or target trial emulation studies are needed before recommending widespread adoption, as certainty of evidence was very low across all outcomes. Full article
Show Figures

Figure 1

Back to TopTop